RegenMed 2.0: Prospects for a Second Generation of Stem Cell-Based Therapeutics
Tuesday, April 22
5:00 pm
Early private investment in stell cell-based regenerative medicine did not translate into breakthrough clinical successes. However, as stem cell research and technology matures, a second generation of stem cell-based therapeutics may overcome the manufacturing, delivery, safety, regulatory and commercial hurdles encountered by early participants.
Improved methods to reproducibly and irreversibly differentiate stem cells should benefit clinical trial design as well as commercial scale manufacturing and GMP regulations. In addition, new haplotype matching technology may allow for more commercially viable allogenic therapeutics to be developed. Will these new technologies spawn a new generation of stem cell-based company formation, or will it take a definitive commercial success to stimulate new capital commitments? Please join us to discuss the prospects for RegenMed 2.0 with a leading stem cell venture capital investor, translational scientist, physician, and regulatory expert.
Moderator:
- Dr. Leonide Saad, PhD, Vice President, Proteus Venture Partners
Panelists:
- Stephen Badylak, MD, PhD, DVM, Professor, Department of Surgery and Deputy Director, McGowan Institute for Regenerative Medicine at the University of Pittsburgh
- David Scadden, MD, Co-Chair, Department of Stem Cell and Regenerative Biology, Harvard University; Co-Director, Harvard Stem Cell Institute; and Director, MGH Center for Regenerative Medicine
- Mark Furth, PhD, Technical Development Officer, Wake Forest Institute of Regenerative Medicine
Who's Who
- Dr. Leonide Saad, PhD, Vice President, Proteus Venture Partners
Leonide Saad brings several years of experience to the field of Regenerative Medicine. With experience encompassing fundamental and clinical research as well as regulatory work, Dr. Saad has worked across the entire R&D chain of Regenerative Medicine. Prior to joining Proteus Venture Partners, Dr. Saad led pioneering research at MIT, Harvard Medical School (Brigham and Women°Øs Hospital) and Veterans°Ø Affair Boston, in the field of tissue engineering of the intervertebral disc; He participated in research efforts in spinal cord, cartilage, tendon, heart and brain tissue engineering.
In addition to being a scientist, Dr. Saad also has investment banking and startup experience and helped the formation of firms in IT, non-profit and tissue engineering. Dr. Saad has also worked in Europe and China. He is a member of Sigma-Xi and TERMIS and peer reviewer in scientific journals of Regenerative Medicine. He was MIT Presidential and Whitaker Health Sciences Fund Fellow and holds a Ph.D. from MIT with core research in Tissue Engineering/Regenerative Medicine.
- Stephen Badylak, MD, PhD, DVM, Professor, Department of Surgery and Deputy Director, McGowan Institute for Regenerative Medicine at the University of Pittsburgh
Dr. Badylak holds over 40 US patents and 200 patents worldwide and has authored more than 170 scientific publications and 12 book chapters. He has served as the Chair of the Purdue University Tissue Engineering Advisory Board and as chair of several Study Sections for the National Institutes of Health (NIH), including the Bioengineering, Technology, and Surgical Sciences Study Section. Dr. Badylak has either chaired or been a member of the Scientific Advisory Board to several major medical device companies. He is a Fellow of the American Institute for Medical and Biological Engineering. He is a charter member and president-elect of the North American delegate to the Tissue Engineering Regenerative Medicine International Society (TERMIS).
- David Scadden, MD, Co-Chair, Department of Stem Cell and Regenerative Biology, Harvard University; Co-Director, Harvard Stem Cell Institute; and Director, MGH Center for Regenerative Medicine
David Scadden, MD, is Co-Chair, Department of Stem Cell and Regenerative Biology at Harvard University, Co-Director, Harvard Stem Cell Institute and Director of MGH Center for Regenerative Medicine. In addition, Dr. Scadden is Chief, Hematologic Malignancies at MGH Cancer Center. The focus of his laboratory is hematopoietic stem cell biology, targeting three problems limiting the ability of stem cells to be used more effectively as therapy: stem cell number, stem cell localization as delivery of stem cell to specific sites is critical for their application clinically, and viewing the stem cell through the microenvironment in which it resides.
- Mark Furth, PhD, Technical Development Officer, Wake Forest Institute of Regenerative Medicine
Mark Furth, PhD, is the Technical Development Officer at Wake Forest Institute of Regenerative Medicine. Dr. Furth is a molecular biologist with fifteen years of executive experience in the biopharmaceutical industry. He had previously served as Senior Vice President - Research at Incara Pharmaceuticals. In that role Dr. Furth provided leadership and direction for expanding the applications of Incara's technologies in tissue protection, repair and regeneration, including the use of adult liver stem cells for gene therapy and genomics and the use of Incara's catalytic antioxidants in cell therapy and metabolic diseases. From 1997 through 2000 he was Chief Scientific Officer of PPD Discovery, a company focused on drug discovery platforms including functional genomics and combinatorial chemistry, and then served the same role at PPGx, a pharmacogenomics company initially formed as a joint venture between PPD and Axys Pharmaceuticals. He was also previously Vice President, Molecular Sciences of Glaxo Wellcome (now GlaxoSmithKline) and Vice President for Technology of Regeneron Pharmaceuticals, which he joined as the first member of the research staff.